

Strides subsidiary gets FDA nod for cancer drug

04 September 2012 | Regulatory | By BioSpectrum Bureau

Strides subsidiary gets FDA nod for cancer drug



Singapore: Onco Therapies Limited, a wholly-owned subsidiary of Strides Arcolab, received final abbreviated new drug application (ANDA) approval for Vinorelbine injection 10 mg/mL packaged in 10 mg/1 mL and 50 mg / 5mL single-dose vials.

Vinorelbine is part of Onco Therapies' oncology portfolio that has been licensed to Pfizer for the US market and the product is available for immediate launch.

Vinorelbine is used to treat various types of cancer. It is a chemotherapy drug that works by slowing or stopping cancer cell growth.